University of Hertfordshire

From the same journal

By the same authors

Cannabis; epidemiological, neurobiological and psychopathological issues: an update

Research output: Contribution to journalArticlepeer-review

Standard

Cannabis; epidemiological, neurobiological and psychopathological issues: an update. / De Luca, Maria Antonietta; Di Chiara, Gaetano; Cadoni, Cristina; Lecca, Daniele; Orsolini, Laura; Papanti, Duccio; Corkery, John; Schifano, Fabrizio.

In: CNS & Neurological Disorders - Drug Targets, Vol. 16, 13.04.2017.

Research output: Contribution to journalArticlepeer-review

Harvard

APA

Vancouver

Author

De Luca, Maria Antonietta ; Di Chiara, Gaetano ; Cadoni, Cristina ; Lecca, Daniele ; Orsolini, Laura ; Papanti, Duccio ; Corkery, John ; Schifano, Fabrizio. / Cannabis; epidemiological, neurobiological and psychopathological issues: an update. In: CNS & Neurological Disorders - Drug Targets. 2017 ; Vol. 16.

Bibtex

@article{4722066ac2514586888c53c179d9801b,
title = "Cannabis; epidemiological, neurobiological and psychopathological issues: an update",
abstract = "Cannabis is the illicit drug with both the largest current levels of consumption and the highest reported lifetime prevalence levels in the world. Across different countries, the prevalence of cannabis use varies according to the individual income, with the highest use being reported in North America, Australia and Europe. Despite its {\textquoteleft}soft drug{\textquoteright} reputation, cannabis misuse may be associated with several acute and chronic adverse effects. The present article aims at reviewing several papers on epidemiological, neurobiological and psychopathological aspects of the use of cannabis. The PubMed database was here examined in order to collect and discuss a range of identified papers. Cannabis intake usually starts during late adolescence/early adulthood (15-24 years) and drastically decreases in adulthood with the acquisition of working, familiar and social responsibilities. Clinical evidence supports the current socio-epidemiological alarm concerning the increased consumption among youngsters and the risks related to the onset of psychotic disorders. The mechanism of action of cannabis presents some analogies with other abused drugs, e.g. opiates. Furthermore, it has been well demonstrated that cannabis intake in adolescence may facilitate the transition to the use and/or abuse of other psychotropic drugs, hence properly being considered a {\textquoteleft}gateway drug{\textquoteright}. Some considerations on synthetic cannabimimetics are provided here as well. In conclusion, the highest prevalence of cannabis use and the social perception of a relatively low associated risk are in contrast with current knowledge based on biological and clinical evidence. Indeed, there are concerns relating to cannabis intake association with detrimental effects on both cognitive impairment and mental health.",
keywords = "cannabis, Δ9-THC, addiction, cannabimimetics, gateway hypothesis, dopamine, medical marijuana",
author = "{De Luca}, {Maria Antonietta} and {Di Chiara}, Gaetano and Cristina Cadoni and Daniele Lecca and Laura Orsolini and Duccio Papanti and John Corkery and Fabrizio Schifano",
note = "This document is the Accepted Manuscript version of the following article: Maria Antonietta De Luca, Gaetano Di Chiara, Cristina Cadoni, Daniele Lecca, Laura Orsolini, Duccio Papanti, John Corkery, Fabrizio Schifano, 'Cannabis; Epidemiological, Neurobiological and Psychopathological Issues: An Update', CNS & Neurological Disorders - Drug Targets, Vol. 16, 2017. The published manuscript is available at EurekaSelect via https://doi.org/10.2174/1871527316666170413113246. Published by Bentham Science. ",
year = "2017",
month = apr,
day = "13",
doi = "10.2174/1871527316666170413113246",
language = "English",
volume = "16",
journal = "CNS & Neurological Disorders - Drug Targets",
issn = "1871-5273",
publisher = "Bentham Science Publishers B.V.",

}

RIS

TY - JOUR

T1 - Cannabis; epidemiological, neurobiological and psychopathological issues: an update

AU - De Luca, Maria Antonietta

AU - Di Chiara, Gaetano

AU - Cadoni, Cristina

AU - Lecca, Daniele

AU - Orsolini, Laura

AU - Papanti, Duccio

AU - Corkery, John

AU - Schifano, Fabrizio

N1 - This document is the Accepted Manuscript version of the following article: Maria Antonietta De Luca, Gaetano Di Chiara, Cristina Cadoni, Daniele Lecca, Laura Orsolini, Duccio Papanti, John Corkery, Fabrizio Schifano, 'Cannabis; Epidemiological, Neurobiological and Psychopathological Issues: An Update', CNS & Neurological Disorders - Drug Targets, Vol. 16, 2017. The published manuscript is available at EurekaSelect via https://doi.org/10.2174/1871527316666170413113246. Published by Bentham Science.

PY - 2017/4/13

Y1 - 2017/4/13

N2 - Cannabis is the illicit drug with both the largest current levels of consumption and the highest reported lifetime prevalence levels in the world. Across different countries, the prevalence of cannabis use varies according to the individual income, with the highest use being reported in North America, Australia and Europe. Despite its ‘soft drug’ reputation, cannabis misuse may be associated with several acute and chronic adverse effects. The present article aims at reviewing several papers on epidemiological, neurobiological and psychopathological aspects of the use of cannabis. The PubMed database was here examined in order to collect and discuss a range of identified papers. Cannabis intake usually starts during late adolescence/early adulthood (15-24 years) and drastically decreases in adulthood with the acquisition of working, familiar and social responsibilities. Clinical evidence supports the current socio-epidemiological alarm concerning the increased consumption among youngsters and the risks related to the onset of psychotic disorders. The mechanism of action of cannabis presents some analogies with other abused drugs, e.g. opiates. Furthermore, it has been well demonstrated that cannabis intake in adolescence may facilitate the transition to the use and/or abuse of other psychotropic drugs, hence properly being considered a ‘gateway drug’. Some considerations on synthetic cannabimimetics are provided here as well. In conclusion, the highest prevalence of cannabis use and the social perception of a relatively low associated risk are in contrast with current knowledge based on biological and clinical evidence. Indeed, there are concerns relating to cannabis intake association with detrimental effects on both cognitive impairment and mental health.

AB - Cannabis is the illicit drug with both the largest current levels of consumption and the highest reported lifetime prevalence levels in the world. Across different countries, the prevalence of cannabis use varies according to the individual income, with the highest use being reported in North America, Australia and Europe. Despite its ‘soft drug’ reputation, cannabis misuse may be associated with several acute and chronic adverse effects. The present article aims at reviewing several papers on epidemiological, neurobiological and psychopathological aspects of the use of cannabis. The PubMed database was here examined in order to collect and discuss a range of identified papers. Cannabis intake usually starts during late adolescence/early adulthood (15-24 years) and drastically decreases in adulthood with the acquisition of working, familiar and social responsibilities. Clinical evidence supports the current socio-epidemiological alarm concerning the increased consumption among youngsters and the risks related to the onset of psychotic disorders. The mechanism of action of cannabis presents some analogies with other abused drugs, e.g. opiates. Furthermore, it has been well demonstrated that cannabis intake in adolescence may facilitate the transition to the use and/or abuse of other psychotropic drugs, hence properly being considered a ‘gateway drug’. Some considerations on synthetic cannabimimetics are provided here as well. In conclusion, the highest prevalence of cannabis use and the social perception of a relatively low associated risk are in contrast with current knowledge based on biological and clinical evidence. Indeed, there are concerns relating to cannabis intake association with detrimental effects on both cognitive impairment and mental health.

KW - cannabis

KW - Δ9-THC

KW - addiction

KW - cannabimimetics

KW - gateway hypothesis

KW - dopamine

KW - medical marijuana

U2 - 10.2174/1871527316666170413113246

DO - 10.2174/1871527316666170413113246

M3 - Article

VL - 16

JO - CNS & Neurological Disorders - Drug Targets

JF - CNS & Neurological Disorders - Drug Targets

SN - 1871-5273

ER -